Background. This study provides a summary of the 2008 ERA-EDTA Registry Report (this report is available at www.era-edta-reg.org). Methods. The data on renal replacement therapy (RRT) were available from 55 national and regional registries in 30 countries in Europe and bordering the Mediterranean Sea. Datasets with individual patient data were received from 36 registries, whereas 19 registries contributed data in aggregated form. We presented incidence and prevalence of RRT, and transplant rates. Survival analysis was solely based on individual patient records. Results. In 2008, the overall incidence rate of RRT for end-stage renal disease (ESRD) among all registries reporting to the ERA-EDTA Registry was 122 per million population (pmp), and the prevalence was 644 pmp. Incidence rates varied from 264 pmp in Turkey to 15 pmp in Ukraine. The mean age of patients starting RRT in 2008 ranged from 69 years in Dutch-speaking Belgium to 44 years in Ukraine. The highest prevalence of RRT for ESRD was reported by Portugal (1408 pmp) and the lowest by Ukraine (89 pmp). The prevalence of haemodialysis on 31 December 2008 ranged from 66 pmp (Ukraine) to 875 pmp (Portugal) and the prevalence of peritoneal dialysis from 8 pmp (Montenegro) to 115 pmp (Denmark). In Norway, 70% of the patients on RRT on 31 December 2008 were living with a functioning graft (572 pmp). In 2008, the number of transplants performed pmp was highest in Spain (Catalonia) (64 pmp), whereas the highest transplant rates with living-donor kidneys were reported from the Netherlands (25 pmp) and Norway (21 pmp). In the cohort 1999-2003, the unadjusted 1-, 2-and 5-year survival of patients on RRT was 80.8% (95% CI: 80.6-81.0), 69.1% (95% CI: 68.9-69.3) and 46.1% (95% CI: 45.9-46.3), respectively.
Introduction
This summary of the 2008 ERA-EDTA Registry Report includes the data on renal replacement therapy (RRT) from 55 national and regional registries in 30 countries in Europe and bordering the Mediterranean Sea ( Figure 1 ). The renal registries provided datasets with individual patient data (36 registries) or in aggregated form (19 registries) . The data from all registries were used to present incidence and prevalence of RRT data as well as transplant rates. Survival analyses used the data from countries and regions that provided individual patient records. More detailed data than those presented in this paper can be found in the 2008 ERA-EDTA Registry Report [1] which is available at www.era-edta-reg.org.
Incidence of RRT for ESRD across Europe
Incidence is the number of new cases of a condition during a specific period of time which, in this annual report, is a year (2008) . In 2008, the overall incidence rate of RRT for endstage renal disease (ESRD) among all registries reporting to the ERA-EDTA Registry was 122 per million population (pmp). Figure 2 shows that the highest incidence rates at Day 1 were reported by Turkey (264 pmp), Portugal (232 pmp) and Greece (199 pmp), whereas incidence rates below 100 pmp where reported by Ukraine (15 pmp), Montenegro (30 pmp), Russia (37 pmp), Estonia (66 pmp), Iceland (73 pmp), Latvia (95 pmp), Finland (95 pmp), Romania (96 pmp) and Spain (Castile-La Mancha) (98 pmp). The incidence rate of RRT for diabetic ESRD was highest in Turkey (80 pmp), Israel (77 pmp) and Slovakia (71 pmp), while the registries of Iceland, Romania, Ukraine, Montenegro, Russia, Estonia and Latvia reported incidence rates for ESRD due to diabetes mellitus below 20 pmp (Figure 2 ). Table 1 shows the incidence rate of RRT over the period 2004-08 for countries and regions providing individual patient data, adjusted for age and gender distribution.
For the age group 0-19 years at the start of RRT, the data were available for 14 registries of 11 countries including those of Austria, Denmark, Finland, Greece, Iceland, Norway, Romania, Spain (Andalusia), Spain (Basque country), Spain (Catalonia), Spain (Valencian region), Sweden, the Netherlands and the UK (Scotland). As numbers of children starting RRT were low we present averages for [2007] [2008] (Table 2) . For an overview of paediatric RRT data collected by the ESPN/ERA-EDTA Registry, please visit www.espn-reg.org. Figure 3 shows that the mean age of patients starting RRT in 2008 ranged from 44 years in Ukraine to 69 years in Dutch-speaking Belgium.
The incidence of the different treatment modalities was measured as number of patients pmp on treatment modality at Day 91 of RRT (Table 3 ). Whereas incidence rates of haemodialysis were highest in Greece (160 pmp), Israel (157 pmp), and in Dutch-and French-speaking Belgium (150 pmp and 153 pmp respectively), the highest incidence rates for peritoneal dialysis were reported from Sweden (37 pmp), Denmark (34 pmp) and Finland and Iceland (both 28 pmp). The highest incidence rates of patients living on a functioning graft at Day 91 of RRT were seen in Norway (15 pmp) and the Netherlands (11 pmp).
Prevalence of RRT for ESRD across Europe
Prevalence is the number of people in a given population with a particular disease at a given time, in this annual report at December 31, 2008. The overall prevalence among all registries reporting to the ERA-EDTA Registry was 644 pmp. Figure 4 shows that the prevalence of RRT pmp at 31 December 2008 was highest in Portugal (1408 pmp), Belgium (French-speaking) (1153 pmp) and Spain (Catalonia) (1124 pmp). The lowest prevalence was reported by Ukraine (89 pmp) and Russia (165 pmp). Table 4 shows the overall prevalence of RRT, adjusted for age and gender distribution.
Only a limited number of registries provided complete data for prevalent patients in the age group 0-19 years in 2008, including those of Austria, Denmark, Finland, Greece, Iceland, Norway, Romania, Spain (Andalusia), Spain (Basque country), Spain (Catalonia), Spain (Valencian region), Sweden, the Netherlands and the UK (Scotland). The prevalence for age group 0-19 years is presented in Table 5 . The mean age of patients on RRT on 31 December 2008 ranged from 44 years (Ukraine) to 64 years (Dutch-speaking Belgium and Italy) for registries providing data on both dialysis and transplant patients ( Figure 5 ).
The prevalence of haemodialysis on 31 December 2008 was highest in Portugal (875 pmp), Greece (753 pmp) and Italy (16 of 20 regions) (739 pmp), and the lowest in Ukraine (66 pmp), Russia (118 pmp) and Iceland (154 pmp) ( Table 6 ). The prevalence of peritoneal dialysis was highest in Denmark (115 pmp), the UK, Wales (102 pmp) and Sweden (92 pmp), whereas the lowest prevalence of this treatment was reported in Montenegro (8 pmp), Ukraine (11 pmp) and Russia (12 pmp). In Norway, 70% of the patients on RRT were living with a functioning graft (572 pmp). Conflict of interest statement. None declared. 
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Appendix
Statistical methods Table 8 The For the analysis of patient survival on RRT, the day at the start of RRT was taken as the starting point, and the event studied was death. Censored observations were recovery of renal function, loss to follow-up and end of follow-up time.
For the analysis of patient survival on dialysis, the first day on dialysis was the starting point, the event was death, and reasons for censoring were recovery of renal function, loss to follow-up, end of follow-up time and renal transplantation. For the analysis of patient and graft survival after transplantation, the date of the first renal transplantation was defined as the first day of follow-up. For the patient survival after transplantation, the event studied was death, and for the graft survival, the events were graft failure and death. Reasons for censoring were loss to follow-up and end of follow-up time. Figure 6 For the analyses of patient survival on dialysis, the starting point was Day 91 on dialysis. Analyses were adjusted for the fixed values of age (60 years), gender (60% men), and primary renal disease (20% diabetes mellitus, 17% hypertension/renal vascular disease, 15% glomerulonephritis and 48% other causes). For the analyses of patient survival after transplantation, the starting point was the time of the first transplant. Analyses were adjusted for the fixed values of age (45 years), gender (60% men), and primary renal disease (10% diabetes mellitus, 8% hypertension/renal vascular disease, 28% glomerulonephritis and 54% other causes).
Figures 7 and 8
For the analyses presented in each figure, the starting point was Day 91 on dialysis. Analyses were adjusted for the fixed values of age (60 years) and gender (60% men). 
